Leprosy is an ancient disease that has been all but eliminated in high-income countries but continues to impact the most marginalized communities in low- and middle-income countries. Current treatment regimens are long and toxic to patients, placing a significant burden on those affected by the disease and reducing the chances that patients will successfully complete treatment.
Johnson & Johnson is committed to advancing a safe and effective new treatment regimen that helps global efforts to tackle leprosy. The bacteria that causes TB and the one that causes leprosy are in the same family, so we’re leveraging our deep experience and knowledge to identify new approaches to treating this disease. Ultimately, we hope to help ensure access to the best science available, enabling those living with leprosy the chance to live healthier and more productive lives.